Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Radiation Oncology

Fig. 2

From: Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol

Fig. 2

Dose distribution. Illustrates a thin slice computer tomography based 3D model of the implant, with optimized individual dose distribution to the target volume (V100 = within the red isodose). Hot (V150 = within the blue isodose) and cold (V50 = within the yellow isodose) spots were set according to biological needs: to areas of residual macroscopic tumor we applied higher local doses and organs at risk received less than the reference dose

Back to article page